Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03838094

Evaluation of MTA Versus Biodentine as Pulpotomy Agents in Immature First Permanent Molars

Clinical and Radiographic Evaluation of MTA Versus Biodentine as Pulpotomy Agents in Immature First Permanent Molars: A Randomized Clinical Trial

Sponsor: Cairo University

Conditions Carious Exposure of Pulp

Interventions Biodentine MTA

Updated 4 times since 2019 Last updated: Feb 8, 2019 Started: Feb 29, 2016 Primary completion: Aug 31, 2018 Completion: Sep 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03838094, this PHASE1/PHASE2 trial focuses on Carious Exposure of Pulp and remains completed. Sponsored by Cairo University, it has been updated 4 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Mar 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cairo University
Gihan M Abuelniel ,PhD

Data source: Cairo University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.